Active substanceTopiramateTopiramate
Similar drugsTo uncover
  • Maxitopyr®
    pills inwards 
    Aktavis, AO     Iceland
  • Rosimat
    pills inwards 
  • Topalepsin®
    pills inwards 
    AKRIKHIN HFK, JSC     Russia
  • Topamax®
    capsules inwards 
  • Topamax®
    capsules inwards 
  • Topiramate
    pills inwards 
    BIOKOM, CJSC     Russia
  • Topiramate
    pills inwards 
    ALSI Pharma, ZAO     Russia
  • Topiramate
    pills inwards 
    NIZHFARM, JSC     Russia
  • Topiramate
    pills inwards 
  • Topiramate
    pills
  • Topiramate Canon
    pills inwards 
  • Topiramate-Vial
    pills inwards 
    VIAL, LLC     Russia
  • Topiramate-Teva
    pills inwards 
  • Topiromax®
    capsules inwards 
    VEROPHARM SA     Russia
  • Topsaver
    capsules inwards 
  • Topsaver
    pills inwards 
  • Torale®
    pills inwards 
    LEKKO, ZAO     Russia
  • Thorapimat
    pills inwards 
  • Epimax
    pills inwards 
    VALENTA PHARM, PAO     Russia
  • Epitope
    pills inwards 
  • Dosage form: & nbspfilm-coated tablets
    Composition:

    Composition per one tablet:

    Dosage of 25 mg

    Core:

    active substance: topiramate - 25.00 mg;

    Excipients: corn starch - 29.00 mg; lactose monohydrate - 25.00 mg; cellulose microcrystalline - 21.48 mg; Povidone K-30 - 1.75 mg; croscarmellose sodium - 1.25 mg; talc - 1.10 mg; magnesium stearate - 1.10 mg; silicon dioxide colloidal - 1,00 mg; sodium carboxymethyl starch - 0.20 mg; methyl parahydroxybenzoate 0.10 mg; propyl parahydroxybenzoate 0.02 mg;

    Sheath:

    white film coating - 3.00 mg [hypromellose 15 cps - 1.52 mg; dibutyl sebacate 0.43 mg; hypromellose 5 cP - 0.30 mg; silicon dioxide colloidal - 0.18 mg; titanium dioxide - 0.45 mg; talc-0.12 mg].

    Dosage 50 mg

    Core:

    active substance: topiramate - 50,00 mg;

    Excipients: corn starch - 43.77 mg; lactose monohydrate - 37.00 mg; microcrystalline cellulose - 30,00 mg; Povidone K-30 - 2.60 mg; croscarmellose sodium - 2.25 mg; talc - 1.70 mg; magnesium stearate - 1.73 mg; silicon dioxide colloidal - 1,50 mg; sodium carboxymethyl starch - 4.25 mg; methylparahydroxybenzoate 0.17 mg; propyl parahydroxybenzoate 0.03 mg;

    Sheath:

    white film coating - 5.00 mg [hypromellose 15 cP - 2.54 mg; dibutyl sebacate - 0.71 mg; hypromellose 5 cP - 0.51 mg; silicon colloidal dioxide - 0.31 mg; titanium dioxide - 0.75 mg; talc - 0.18 mg].

    Dosage of 100 mg

    Core:

    active substance: topiramate - 100.00 mg;

    Excipients: corn starch - 37,50 mg; lactose monohydrate - 22.36 mg; cellulose microcrystalline - 24.00 mg; povidone K-30 - 3.00 mg; croscarmellose sodium - 2.50 mg; talc - 1.90 mg; magnesium stearate - 1.95 mg; silicon dioxide colloidal - 1,55 mg; sodium carboxymethyl starch - 4.50 mg; methylparahydroxybenzoate 0.20 mg; propyl parahydroxybenzoate 0.04 mg;

    Sheath:

    white film coating - 6.50 mg [hypromellose 15 cP - 3.34 mg; dibutyl sebacate 0.94 mg; hypromellose 5 cP - 0.67 mg; silicon dioxide colloidal - 0.40 mg; titanium dioxide - 0.90 mg; talc - 0.25 mg].

    Description:Round biconvex tablets covered with a film coat of white or almost white color; On the fracture, a shell and a nucleus of white or almost white color are visible; 50 mg tablets are at risk from one side.
    Pharmacotherapeutic group:Antiepileptic remedy
    ATX: & nbsp

    N.03.A.X   Other antiepileptic drugs

    N.03.A.X.11   Topiramate

    Pharmacodynamics:

    Topiramate-Vial is an antiepileptic drug belonging to the class of sulfamate-substituted monosaccharides. The exact mechanism of action is unknown. Based on the results of electrophysiological and biochemical studies on the culture of neurons, three properties have been identified that can contribute to the anticonvulsant activity of topiramate. Topiramate blocks sodium channels and suppresses the occurrence of repeated action potentials against a background of prolonged depolarization of the neuron membrane. Topiramate increases the activity of gamma-aminobutyric acid (GABA) with respect to some subtypes of GABA receptors (including GABAAreceptors) and increases the ability of GABA to increase the flow of chloride ions into neurons, topiramate potentiates activity this inhibitory neurotransmitter. This effect is not blocked by flumazenil, a benzodiazepine receptor antagonist. Topiramate does not increase the duration of the channels in the open state, which distinguishes it from barbiturates, which modulate the activity of the GABA themselvesAreceptors. Since the anticonvulsant effect of topiramate differs significantly from that of benzodiazepines,it is able to modulate the action of subtypes of GABAAreceptors insensitive to benzodiazepines. Topiramate prevents activation of kainate sensitivity of the kainate / AMPK subtype (α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid) receptors for glutamate, does not affect activity N-methyl-D-aspartate (NMDA) with respect to the subtype NMDAreceptors. These effects of topiramate are dose-dependent at a drug concentration in the plasma from 1 to 200 μmol / L, with a minimum activity ranging from 1 to 10 μmol / L. Besides, topiramate inhibits the activity of some isoenzymes of carbonic anhydrase. By the severity of this pharmacological effect topiramate is significantly inferior to acetazolamide - a known inhibitor of carbonic anhydrase, therefore this activity of topiramate is not considered the main component of its antiepileptic activity.

    In animal studies, it has been established that topiramate has anticonvulsant activity in tests with maximum electric shock in rats and mice. Effective in models of rodent epilepsy, including tonic convulsions, spontaneous epilepsy of rats, tonic-clonic convulsions caused by the excitation of the amygdala or global ischemia. Topiramate is ineffective in clonic convulsions caused by a GABA receptor antagonist - pentylenetetrazole. With the simultaneous administration of mice with topiramate with carbamazepine or phenobarbital synergism of anticonvulsant effect was noted, with phenytoin an additive effect. In controlled clinical trials of combination of topiramate with other anticonvulsants, a correlation between its concentration and clinical efficacy was not revealed. There is no information about addiction.

    Absenses: two small studies of topiramate in children aged 4-11 years have been carried out. One included 5 children, and the other 12, until it was prematurely completed due to a lack of therapeutic effect. Doses used in these studies were approximately up to 12 mg / kg in the study TOPAMAT-Abs-001 and in the study CAPSS-326 the maximum of the two doses was 9 mg / kg / day or 400 mg / day. These studies do not give sufficient grounds for a conclusion about effectiveness and safety.

    Pharmacokinetics:

    In comparison with other anticonvulsants, topiramate has a long half-life, linear kinetics, mainly renal clearance, low association with plasma proteins and the absence of clinically significant active metabolites. The powerful inducing effect on microsomal enzymes of the liver is not peculiar, its reception is carried out independently of the food intake, concentration monitoring is not required. According to the results of clinical studies, the relationship between the plasma concentration of topiramate and its efficacy or undesirable reactions has not been established.

    Absorption

    Topiramate is absorbed quickly and well. Its bioavailability is 81%. After oral administration of 100 mg of topiramate, the maximum concentration in the plasma (CmAh) 1.5 mg / min is achieved within 2-3 hours. Eating does not have a clinically significant effect on the bioavailability of topiramate.

    Distribution

    Plasma proteins bind 13-17% of topiramate. Places of binding of topiramate on erythrocytes are saturated at its concentration in plasma more than 4 mg / ml. The volume of distribution is inversely proportional to the dose. After a single dose of up to 1200 mg, the average volume of distribution (Vd) is 0.55-0.8 l / kg. Value Vd depends on the sex: in women it is about 50% of the values ​​observed in men, which is associated with a higher content of adipose tissue in the body of women (this has no clinical significance).

    Metabolism

    After ingestion, healthy volunteers metabolize about 20% of the dose. However, in patients receiving concomitant therapy with antiepileptic drugs that are inducers of microsomal liver enzymes, the metabolism of topiramate rises to 50%. From the plasma, urine and human feces, six practically inactive metabolites, formed by hydroxylation, hydrolysis and glucuronation, were isolated and identified. The amount of each metabolite does not exceed 3% of the total reactivity detected upon administration 14C-topiramate. Two metabolites with the greatest structural similarity to topiramate have practically no anticonvulsant activity.

    Excretion

    The main way to excrete unchanged topiramate (81%) and its metabolites are the kidneys. Within 4 days with urine, about 66% of the unchanged 14C-topiramate. After taking 50 and 100 mg of topiramate twice a day, the average renal clearance is 18 and 17 ml / min, respectively. Topiramate is subjected to tubular reabsorption, which is confirmed by the results of a study in rats with simultaneous administration of probenecid: there was a significant increase in renal clearance of topiramate. After Oral administration of plasma clearance of topiramate is 20-30 ml / min.

    Topiramate has a low interindividual variability of plasma concentrations. The pharmacokinetics of topiramate is linear, the plasma clearance remains constant, and the area under the concentration-dose curve (AUC) in the range of doses in healthy volunteers from 100 to 400 mg increases in proportion to the dose. In patients with normal renal function, it may take 4 to 8 days to achieve a stable plasma concentration. The value of CmAfter repeated oral administration, 100 mg of the drug twice a day, on average, was 6.76 μg / ml. After repeated administration of doses of 50 and 100 mg twice daily T1 / 2, the topiramate from plasma averaged 21 hours, while simultaneous application of topiramate in doses of 100-400 mg twice daily with phenytoin or carbamazepine, the concentration of the first in plasma increased in proportion to the dose.

    In patients with impaired renal function medium and severe plasma and renal clearance of topiramate is reduced (creatinine clearance ≤ 70 ml / min), as a consequence, an increase in the equilibrium concentration (Css) topiramate in plasma compared with patients with normal renal function. In addition, patients with impaired renal function require more time to achieve an equilibrium concentration of topiramate in plasma. Patients with moderate or severe renal failure are recommended to use half of the recommended initial and maintenance dose.

    Topiramate is effectively excreted from the plasma by hemodialysis. Long-term hemodialysis can lead to a decrease in the concentration of topiramate in the blood below the amount required to maintain anticonvulsant activity. To avoid a rapid drop in the concentration of topiramate in the plasma during hemodialysis, an additional dose of the drug may be required. When adjusting the dose should be taken into account:

    - duration of hemodialysis;

    - the clearance value of the hemodialysis system used;

    - Effective renal clearance of topiramate in a patient on dialysis. The plasma clearance of topiramate is reduced by an average of 26% in patients with moderate or severe hepatic insufficiency. Therefore, patients with hepatic impairment should be treated topiramate carefully.

    In elderly patients without kidney diseases plasma clearance of topiramate does not change.

    Pharmacokinetics of topiramate in children under 12 years.

    The pharmacokinetic parameters of topiramate in children, as in adults receiving this drug as an auxiliary therapy, are linear in nature, and its clearance is independent of the dose, a Css in plasma increases in proportion to the increase in dose. It should be borne in mind that in children clearance of topiramate is elevated, and its T1 / 2 is shorter. Therefore, at the same dose, based on 1 kg of body weight, the concentrations of topiramate in plasma in children may be lower than in adults. In children, as in adults, antiepileptic drugs that induce microsomal enzymes of the liver cause a decrease in the concentrations of topiramate in plasma.

    Indications:

    Epilepsy:

    In monotherapy:

    - As a monotherapy in adults and children over 6 years of age: partial (with or without secondary generalization) or primary generalized tonic-clonic convulsions.

    In the combination therapy:

    - partial (with secondary generalization or without) or generalized tonic-clonic seizures in adults and children older than 3 years;

    - seizures associated with Lennox-Gastaut syndrome, in adults and children older than 3 years.

    Migraine:

    - Prevention of migraine attacks in adults after a thorough evaluation of all possible alternative treatments. Topiramate It is not intended for the treatment of acute migraine attacks.

    Contraindications:

    - Hypersensitivity to any of the components of the drug;

    - Pregnancy;

    - the period of breastfeeding;

    - Children under 6 years of age with monotherapy, up to 2 years in the combined therapy of epilepsy; children under 18 years of age when used for migraine prevention;

    - prevention of migraine in pregnant women or women of childbearing age who do not use effective contraception;

    - lactose intolerance, lactase deficiency, glucose-galactose malabsorption.

    Carefully:

    - Renal and hepatic insufficiency;

    - nefrourolitiaz (including in the past and in a family anamnesis);

    - hypercalciuria.

    Pregnancy and lactation:

    In mice, rats, rabbits topiramate is teratogen. Penetrates through the placental barrier in rats. Special controlled studies in which topiramate would be used to treat pregnant women, was not conducted. Topiramate may cause harm to the fetus when used in pregnant women. Pregnancy records according to the UK Pregnancy Registry and Pregnancy Registry "Antiepileptic drug of North America" ​​in infants exposed to intrauterine exposure to monotherapy with topiramate in the first trimester have an increased risk of developing congenital malformations (eg, craniofacial defects such as cleft lip or palate, hypospadias and anomalies in the development of various organs and systems of the body). It was also found that with the use of topiramate as monotherapy, the incidence of severe congenital malformations was three times higher than that of peers whose mothers did not take anticonvulsants. In addition, in the treatment group of topiramate, compared with the control group, the likelihood of having children with low body weight increases. In addition, pregnancy records and other studies indicate that the risk of developing teratogenic effects in combination treatment with antiepileptic drugs is higher than with monotherapy.

    The use of topiramate in pregnancy is justified only if the potential benefit of using the drug for the mother exceeds the possible risk to the fetus. When treating and counseling women with childbearing potential, the attending physician must weigh the relationship between the benefits and risks of treatment and consider alternative treatment options. Women of childbearing age are recommended to use reliable methods of contraception. If topiramate is used during pregnancy or the patient becomes pregnant during the period of taking this drug, it should be warned about the potential risk to the fetus.

    Topiramate penetrates into breast milk in animals. The ability to penetrate human milk has not been studied. Based on the results of limited observations, a high content of topiramate in breast milk is established. For the duration of treatment, breastfeeding should be discontinued or the drug should be discontinued, and the importance of the drug to the mother should be borne in mind.

    Epilepsy appointment topiramata during pregnancy should be prescribed after exhaustive informing the woman about the known risks of uncontrolled epilepsy for pregnancy and the potential risks of the drug for the fetus.

    Prevention of migraine

    The drug is contraindicated during pregnancy and in women of childbearing age who do not use reliable methods of contraception.

    Dosing and Administration:

    Inside, swallowing the tablet whole, without chewing, regardless of food intake. For optimal control of seizures, it is recommended to begin treatment with low doses with subsequent increase to an effective dose. Monitoring the concentration of topiramate to determine the optimal dose is not required. In rare cases, the simultaneous use of topiramate and phenytoin may require a dose adjustment of the latter. Adding or abolishing phenytoin or carbamazepine with combined therapy with topiramate may require correction of the latter.

    As part of combination therapy

    Adults: Treatment starts with 25-50 mg daily at night for 1 week. Then increase the dose by 25-50 mg per day for 1-2 weeks with a frequency of reception 2 times a day. It is possible to start therapy with lower doses, but this has not been sufficiently studied. If this dosage regimen is intolerant, the dose is increased by a smaller amount or at large intervals. The dose and the frequency of reception are selected depending on the clinical effect.The minimum effective dose for clinical trials is 200 mg / day. The usual daily dose of 200-400 mg (for 2 admission). The maximum daily dose is 1600 mg.

    In some patients, anticonvulsant effect can be achieved with taking topiramate 1 time per day. The presented recommendations for dosing include all adults, including the elderly without concomitant renal pathology.

    Children over 3 years old: the recommended daily dose is 5-9 mg / kg, divided into 2 doses. Treatment begins with a dose of 25 mg (or less at a rate of 1-3 mg / kg / day) at night for 1 week. Then the dose is increased by 1-3 mg / kg / day for 1-2 weeks with the frequency of reception 2 times a day until the optimal clinical effect is achieved. Doses up to 30 mg / kg / day, which were well tolerated, were studied.

    Monotherapy

    With the withdrawal of concomitant antiepileptic drugs for the initiation of monotherapy with topiramate, it is necessary to take into account the possible influence of this step on the frequency of seizures. In cases where, for security reasons, the need for a sharp cancellation concomitant anticonvulsants are not available, a dose of these drugs is recommended to be reduced by one third every 2 weeks.When the inducer eliminates microsomal liver enzymes, the concentration of topiramate in plasma increases. In such situations, in the presence of clinical indications, a reduction in the dose of topiramate may be required.

    Adults: treatment starts with 25 mg at night for 1 week. Then increase the dose by 25-50 mg per day for 1-2 weeks with a frequency of reception 2 times a day. If this dosage regimen is intolerant, the dose is increased by a smaller amount or at large intervals. The dose and the frequency of reception are selected depending on the clinical effect. The recommended initial dose of Topiramate-Vial for monotherapy in adults with newly established epilepsy is 100-200 mg / day, divided into two doses, the maximum recommended dose is 500 mg / day divided into two doses. These doses are recommended for all adults, including the elderly with normal kidney function. Some patients with refractory seizures of epilepsy tolerate monotherapy with topiramate at doses up to 1000 mg per day.

    Children from 6 years old: treatment starts with a dose of 0.5-1 mg / kg at night for 1 week. Then increase the dose by 0.5-1 mg / kg / day for 1-2 weeks, the frequency of reception - 2 times a day.If this dosage regimen is intolerant, the dose is increased by a smaller amount or at large intervals. The dose and the frequency of reception are selected depending on the clinical effect. Depending on the clinical effect, the recommended dose for monotherapy in children from 6 years is 100 mg / day (2 mg / kg per day for children 6-16 years old).

    Migraine

    The recommended total daily dose of topiramate for prevention of migraine attacks is 100 mg and is taken in 2 divided doses. At the beginning of treatment, the patient should take 25 mg of the drug before bedtime for 1 week. Then the dose is increased with an interval of 1 week for 25 mg / day. If the patient does not tolerate such a regime of increasing the dose, then it is possible to increase the intervals between dose increases, or to increase the dose more smoothly. When choosing a dose, it is necessary to be guided by the clinical effect.

    In some patients, a positive result is achieved with a daily dose of topiramate 50 mg. In clinical trials, patients received various daily doses of topiramate, but not more than 200 mg / day. In some patients, this dose can be effective, but caution should be exercised when it is used because of the increased incidence of adverse reactions.Topiramate-Vial is not used to prevent migraine attacks in children due to unproven efficacy and safety of use in this age category.

    Special patient groups

    Renal insufficiency. Patients with renal insufficiency (CC ≤ 70 ml / min) topiramate should be administered with caution, as its plasma and renal clearance decreases. Patients with concomitant renal dysfunction may need more time to achieve an equilibrium concentration at each dose selection stage. Recommended use of half the recommended initial and maintenance dose.

    Hemodialysis. Because the topiramate is removed from the plasma during hemodialysis, on days of hemodialysis, an additional dose of the drug should be prescribed, equal to about half the daily dose. The additional dose should be divided into two doses, taken at the beginning and after completion of the hemodialysis procedure. The additional dose may vary depending on the characteristics of the equipment used for hemodialysis.

    Liver failure. Patients with hepatic insufficiency topiramate should be used with caution.

    Antiepileptic drugs, including topiramate, should be abolished gradually to minimize the possibility of an increase in the frequency of seizures. In clinical studies in adult patients in the treatment of epilepsy, a dose of 50-100 mg per week was reduced, patients taking topiramate in a dose of up to 100 mg per day for the prevention of migraine, the dose was reduced by 25-50 mg per week. Children in clinical studies were withdrawn within 2-8 weeks. If, for medical reasons, rapid suppression of topiramate is required, it is recommended that appropriate monitoring of the patient's condition be performed. The main way of excretion of topiramate and its metabolites in an unchanged form is excretion by the kidneys. The rate of excretion by the kidneys depends on the function of the kidneys and does not depend on age. Patients with moderate or severe renal dysfunction to achieve equilibrium plasma concentrations may need 10-15 days compared to 4-8 days in patients with normal renal function.

    As with the use of other antiepileptic drugs (PEP),The topiramate-Vial dosage adjustment regimen should focus on therapeutic efficacy (i.e., the reduction in the frequency of seizures, the absence of side effects) and should take into account the fact that patients with impaired renal function to establish an equilibrium concentration of topiramate in blood plasma for each dose may need more long time.

    Side effects:

    Safety of application of topiramate for all indications for use was studied in 4111 patients (3182 took topiramate 929 placebo) who participated in 20 double-blind clinical trials, 2847 patients participated in 34 open-label studies. Undesirable effects are presented with a frequency distribution and organ systems. The most common adverse reactions (with a frequency of> 5%) compared with placebo, observed in at least 1 double-blind study were: anorexia, decreased appetite, mental retardation, depression, slurred speech, insomnia, impaired coordination, dizziness, dysarthria, taste disorders, hypoesthesia, lethargy, memory loss, nystagmus,paresthesia, drowsiness, tremor, diplopia, visual impairment, diarrhea, nausea, fatigue, irritability, weight loss. The incidence of side effects was classified as follows: very frequent (≥1 / 10); frequent (≥1 / 100, <1/10); infrequent (≥1 / 1000 and <1/100); rare (≥1 / 10000 and <1/1000) and very rare (<1/10000).

    Infections: very often - nasopharyngitis.

    From the side of the blood and lymphatic system: often - anemia; infrequently - leukopenia, lymphadenopathy, leukopenia, thrombocytopenia, eosinophilia; very rarely - neutropenia.

    From the immune system: often - hypersensitivity; frequency unknown - angioedema, edema of the conjunctiva.

    From the side of metabolism and nutrition: often - anorexia, a decrease in appetite; infrequently - metabolic acidosis, hypokalemia, increased appetite, polydipsia; rarely - hyperchloremic acidosis.

    From the central nervous system: very often - drowsiness, dizziness, paresthesia; often - violation of concentration of attention, convulsions, inhibition, impaired coordination of movements, nystagmus, lethargy, memory impairment, tremor, amnesia, dysarthria, intentional tremor, gait disturbance,Hypesesia, perversion of taste sensations, disturbance of thinking; Cognitive disorders, apathy, mental decline, psychomotor disorders, sedation; infrequently, depression of the visual field, loss of taste sensitivity, hypokinesia, loss of smell, aphasia, apraxia, aura, burning sensation in the limbs or face, cerebellar syndrome, complex partial seizures, convulsions, postural dizziness, dysesthesia, sensitivity disorder, dysgraphia , dyskinesia, dysphasia, dystonia, sensory disturbances, sensation of goosebumps, tonic-clonic seizures by type grand mal, hyperesthesia, hypogeousia, hypokinesia, psychomotor agitation, hyposmia, peripheral neuropathy, parosmia, pre-stupor states, repetitive speech, impaired touch, stupor, clumsiness, fainting, lack of response to stimuli, poor quality of sleep; rarely - apraxia, disturbance of circadian rhythm of sleep, hyperesthesia, hyposmia, essential tremor, anosmia, lack of response to stimuli.

    From the side of the psyche: very often - depression; often - delayed thinking, pronounced speech disorders, anxiety,confusion, insomnia, aggressive reactions, agitation, mood changes, agitation, disorientation, emotional lability, anger, erectile dysfunction, behavior change; infrequent anorgasmia, sexual dysfunction, tearfulness, impaired sexual arousal, dyspharmia, early waking up in the morning, euphoric mood, auditory and visual hallucinations, psychotic disorders, decreased libido and lack of libido, lethargy, intrasomnia, absent-mindedness, upbeat mood, apathy, violation speeches, panic attacks, paranoid states, perseveration of thinking, violation of reading skills, sleep disorders, suicidal ideation or attempts, falling asleep, emotional cold ness, tearfulness; rarely - a sense of despair, mania, panic disorder, hypomania.

    From the gastrointestinal tract and the hepatobiliary system: very often - nausea, diarrhea; often - vomiting, pain in the epigastric region, dyspepsia, dry mouth, abdominal pain, paresthesia of the oral mucosa, gastritis, abdominal discomfort; infrequently - pain in the lower abdomen, constipation,impaired sensation in the oral cavity, gastritis, gastroesophageal reflux, gum bleeding, heaviness in the stomach, bad breath, epigastric discomfort, flatulence, glossodynia, oral pain, pancreatitis, hypersecretion of the salivary glands, thirst; rarely - hepatitis, hepatic insufficiency.

    From the musculoskeletal system and connective tissue: often: myalgia, including the chest, muscle spasms, muscle cramps, muscle weakness, chest pain, arthralgia; infrequently: pain in the side, swelling of the joints, stiffness of the muscles, fatigue of the muscles; rarely: discomfort in the extremities.

    From the genitals and the breast: infrequent - an erection disorder, a violation of sexual function.

    From the CAS side: infrequently bradycardia, including sinus, palpitation, flushing, orthostatic hypotension, hypotension, rarely - Raynaud's syndrome.

    Common violations: very often fatigue; often - asthenia, anxiety, gait disturbance, poor health, anxiety, irritability, fever; infrequently - hyperthermia, thirst, flu-like syndrome, sluggishness, asthenia, cold extremities, allergic reactions, hyperchloremic acidosis, hypokalemia, anxiety, increased appetite, metabolic acidosis, polydipsia, fatigue, weakness; rarely - edema of the face, calcification.

    Ophthalmic disorders: often - diplopia, blurred vision, dry eyes; infrequent - photophobia, blepharospasm, discomfort in the eyes, increased lacrimation, mydriasis, photopsy, presbyopia, scotoma, dry eyes, decreased visual acuity; rarely - transient blindness, unilateral blindness, glaucoma, accommodation disorder, amblyopia, binocular vision impairment, ciliary scotoma, eyelid edema, night blindness; very rarely - closed-angle glaucoma, violations of eyeballs, maculopathy, conjunctival edema.

    From the organ of hearing: often - pain in the ears, ringing in the ears, vertigo; infrequently - deafness, incl. neurosensory and one-sided, hearing loss, discomfort in the ears, hearing loss.

    From the respiratory system: often - shortness of breath, shortness of breath, rhinorrhea, nasal congestion, epistaxis; infrequently - dysphonia, shortness of breath with physical exertion, hypersecretion in the paranasal sinuses.

    From the skin: often - rash, alopecia, itching; infrequently - anhidrosis, vitiligo, oligohydrosis, allergic dermatitis, reddening of the skin, skin pigmentation disorder, itching, macular rash, rashes, face swelling, hives, acne; rarely - polymorphic erythema, paraorbital edema, unpleasant skin odor, Stevens-Johnson syndrome, toxic epidermal necrolysis, focal urticaria.

    From the side of the kidneys and urinary tract: often - nephrolithiasis, dysuria, pollakiuria; infrequently: urolithiasis, hematuria, urinary incontinence, frequent urge to urination, renal colic, renal tubular acidosis of pain in the kidney, infection of the genitourinary system.

    Change in laboratory indicators: very often - a decrease in body weight; often - weight gain; infrequently - kristalluriya, abnormal result of the "tandem gait" test, leukopenia, hypokalemia (serum potassium level lower than 3.5 mmol / l), lowering of leukocyte count, increased activity of "liver" transaminases and alkaline phosphatase; very rarely - a decrease in the content of bicarbonate in the blood (an average of 4 mmol / l).

    Social Disorders - impaired ability to learn.

    In controlled clinical trials, the most common adverse reactions in children (with a frequency of occurrence 2 times more common in children than in adults): decreased appetite, increased appetite, hyperchloremic acidosis, hypokalemia, behavioral disorders, aggression, apathy, insomnia (including disturbance of falling asleep), suicidal thoughts, attention deficit disorder, lethargy, disturbance of circadian rhythms, poor sleep, increased tearfulness, sinus bradycardia, sensitive disorders, gait disorders.

    Adverse reactions observed only in children: eosinophilia, psychomotor hyperactivity, dizziness, vomiting, hyperthermia, learning difficulties.

    Overdose:

    Signs and symptoms of overdose: convulsions, drowsiness, speech and vision impairment, diplopia, thinking disorders, coordination disorders, dizziness, lethargy, stupor, hypotension, abdominal pain, dizziness, agitation and depression, metabolic acidosis. In most cases, the clinical consequences were not severe, but there were deaths after an overdose using a mixture of several medicines, including topiramate. There is a known case of overdose with topiramate in a dose of up to 110 g, which led to coma for 20-24 hours, and then in 3-4 days a full recovery.

    Treatment: there is no specific antidote, if necessary, symptomatic therapy is performed. It is necessary to immediately induce vomiting and rinse the stomach, increase water intake. In studies in vitro it was shown that Activated carbon adsorbs topiramate.

    Hemodialysis is the most effective way of removing topiramate from the body. Patients are advised to adequately increase the amount of fluid consumed.

    Interaction:

    The effect of topiramate on the concentration of other antiepileptic drugs (PEP)

    Simultaneous reception of topiramate with other PEP (phenytoin, carbamazepine, valproic acid, phenobarbital, primidon) does not affect the values ​​of their Css in plasma, with the exception of individual patients, in whom the addition of topiramate to phenytoin may cause an increase in the plasma phenytoin concentration. This may be due to the inhibition of the specific polymorphic isoform of the enzyme of the cytochrome P450 system (isoenzyme CYP2C19). Therefore, every patient who takes phenytoin and in which clinical signs or symptoms of toxicity develop, it is necessary to control the concentration of phenytoin in the plasma.

    In a study of pharmacokinetics in patients with epilepsy, the addition of topiramate to lamotrigine did not affect Css the latter with doses of topiramate 100-400 mg / day. During therapy and after lamotrigine withdrawal (average dose 327 mg / day) Css topiramate did not change.

    Topiramate inhibits the isoenzyme of the cytochrome P450 system (isoenzyme CYP2C19), in connection with which it can interact with its substrate (diazepam, imipramine, moclobemide, proguanil, omeprazole)

    The effect of other PEP on the concentration of topiramate

    Phenytoin and carbamazepine reduce the concentration of topiramate in plasma. Adding or abolishing phenytoin or carbamazepine against a background of treatment with topiramate may require a change in the dose of the latter. Dose should be selected, focusing on achieving the desired clinical effect. The addition or withdrawal of valproic acid does not cause clinically significant changes in the plasma topiramate concentration and, therefore, does not require a change in the dose of the drug.The results of these interactions are summarized in the table below.

    Added PEP

    Concentration of PEP

    Concentration

    Phenytoin

    1 **

    ~ (48%)

    Carbamazepine

    1

    ~ (40%)

    Valproic acid

    1

    1

    Phenobarbital

    1

    NO

    Primidone

    1

    NO

    1 - Lack of effect.

    ** - Increased concentration in single patients.

    ~ - Decreased plasma concentration.

    NO - Not investigated.

    Other drug interactions

    Digoxin. In a single dose study AUC digoxin in plasma with simultaneous administration of topiramate decreased by 12%. The clinical significance of this observation is unclear. In prescribing or reversing topiramate in patients receiving digoxin, special attention should be paid to monitoring the concentration of digoxin in the serum.

    Means that depress the central nervous system. In clinical trials, the effects of simultaneous administration of topiramate with alcohol or other substances depressing the functions of the central nervous system have not been studied. It is not recommended to take topiramate together with alcohol or other drugs that cause depression of the central nervous system.

    Saint John's wort. With the joint intake of drugs based on St. John's wort perfumed (Hypericum perforatum) the concentration of topiramate in plasma may decrease and, as a consequence, the effectiveness of the drug may also decrease. Clinical research of interaction of topiramate and preparations on the basis of St. John's wort holed not carried out.

    Oral contraceptives. In the study of drug interaction with oral contraceptives, in which a combined preparation containing norethisterone (1 mg) and ethinyl estradiol (35 μg), topiramate in doses of 50-800 mg per day did not have a significant effect on the effectiveness of norethisterone and in doses of 50-200 mg per day - on the effectiveness of ethinylestradiol. A significant dose-dependent decrease in the efficacy of ethinylestradiol was observed with doses of topiramate 200-800 mg per day. The clinical significance of the described changes is unclear. The risk of reducing the effectiveness of contraceptives and strengthening breakthrough bleeding should be considered in patients taking oral contraceptives in combination with topiramate. Patients taking estrogen-containing contraceptives should be informed of any changes in the timing and nature of menstruation.The effectiveness of contraceptives can be reduced even in the absence of breakthrough bleeding.

    Lithium. In healthy volunteers, there was a decrease AUC lithium by 18% with the simultaneous administration of topiramate at a dose of 200 mg / day. In patients with manic-depressive psychosis, the use of topiramate at doses up to 200 mg / day did not affect the pharmacokinetics of lithium, but at higher doses (up to 600 mg / day) AUC lithium was increased by 26%. With the simultaneous use of topiramate and lithium, the concentration of the latter in the blood plasma should be monitored.

    Risperidone. Studies of drug interaction with single and multiple administration of topiramate by healthy volunteers and patients with bipolar disorder gave the same results. With the simultaneous administration of topiramate in doses of 250 or 400 mg / day AUC risperidone, taken in doses of 1-6 mg / day, decreases by 16 and 33%, respectively. In this case, the pharmacokinetics of 9-hydroxyrisperidone did not change, and the total pharmacokinetics of the active substances (risperidone and 9-hydroxyrisperidone) changed insignificantly. The change in the systemic effect of risperidone / 9-hydroxyrisperidone and topiramate was not clinically significant, and this interaction is unlikely to be of clinical significance.

    Hydrochlorothiazide. Drug interaction was evaluated in healthy volunteers with separate and combined use of hydrochlorothiazide (25 mg) and topiramate (96 mg). The results of the studies showed that with the simultaneous administration of topiramate and hydrochlorothiazide, an increase in Cmof topiramate by 27% and AUC of topiramate by 29%. The clinical significance of these studies has not been revealed. The administration of hydrochlorothiazide to patients receiving topiramate, may require correction doses of topiramate. The pharmacokinetic parameters of hydrochlorothiazide did not undergo significant changes with concomitant therapy with topiramate.

    Metformin. Drug interactions were evaluated in healthy volunteers who received metformin or a combination of metformin and topiramate. The results of the studies showed that with the simultaneous administration of topiramate and metformin, an increase in Cmah and AUC metformin by 18 and by 25%, respectively, whereas the clearance of metformin with simultaneous application with topiramate was reduced by 20%. Topiramate had no effect on Tmmetformin in the blood plasma. The clearance of topiramate when used concomitantly with metformin is reduced.The degree of revealed changes in clearance is not studied. The clinical significance of the effects of metformin on the pharmacokinetics of topiramate is unclear. In the case of the addition or withdrawal of topiramate in patients receiving metformin, you should carefully monitor the patient's condition for assessing the course of diabetes.

    Pioglitazone. Drug interaction was evaluated in healthy volunteers with separate and simultaneous application of pioglitazone and topiramate. There was a decrease AUC pioglitazone by 15%, without change in Cmah of the drug. These changes were not statistically significant. The active hydroxy metabolite of pioglitazone also showed a decrease in Cmah and AUC by 13 and by 16%, respectively, and for active ketometabolite, a decrease in Cmah and AUC by 60%. The clinical significance of these data is not clear. When patients simultaneously use topiramate and pioglitazone, the patient should be carefully monitored to assess the course of diabetes mellitus.

    Glibenclamide. A drug interaction study was conducted to study the pharmacokinetics of glibenclamide (5 mg / day) in an equilibrium state, applied alone or simultaneously with topiramate (150 mg / day) in type 2 diabetes mellitus patients.When topiramate is used AUC Glibenclamide decreased by 25%. The systemic exposure of 4-trans-hydroxy-glibenclamide and 3-cis-hydroxy-glibenclamide was also reduced (by 13 and 15%, respectively). Glibenclamide did not affect the pharmacokinetics of topiramate in the equilibrium state. Statistically unreliable decrease was detected AUC pioglitazone by 15% in the absence of a change in CmOh. When prescribing topiramate to patients receiving glibenclamide (or the appointment of glibenclamide to patients receiving topiramate), you should carefully monitor the patient's condition for assessing the course of diabetes.

    Other drugs. The simultaneous use of topiramate with drugs predisposing to nephrolithiasis may increase the risk of kidney stones. During treatment with topiramate, the use of drugs should be avoided, predisposing to nephrolithiasis, because they can cause physiological changes that promote nephrolithiasis.

    Valproic acid. The combined use of topiramate and valproic acid in patients who tolerate each drug individually is accompanied by hyperammonemia with or without encephalopathy.In most cases, symptoms and symptoms disappear after the withdrawal of one of the drugs. This adverse event is not caused by pharmacokinetic interaction. The relationship between hyperammonemia and the use of topiramate alone or in combination with other drugs has not been established. With the joint administration of topiramate and valproic acid, hypothermia may occur (unintentional drop in body temperature below 35 ° C) in combination with hyperammonemia or independently. This phenomenon can occur both after the beginning of joint intake of valproic acid and topiramate, and with an increase in the daily dose of topiramate.

    Additional studies of drug interactions: a number of clinical studies have been conducted to evaluate potential drug interactions between topiramate and other drugs. The results of these interactions are summarized in the table below.

    Added medicine

    Concentration of added drugs *

    Concentration of topiramate *

    Amitriptyline

    Increase in Cmah and AUC metabolite of nortriptyline by 20%

    NO

    Dihydroergotamine (oral and oral administration)

    1

    1

    Haloperidol

    Increase AUC metabolite by 31%

    NO

    Propranolol

    Increase in Cmah for 4-OH propranolol by 17% (topiramate 50 mg)

    Increase in Cmah on 9 and 16%; AUC 9 and 17% for propranolol 40 and 80 mg every 12 hours, respectively

    Sumatriptan (oral and subcutaneous)

    1

    NO

    Pisotifen

    1

    1

    Diltiazem

    Decrease AUC diltiazem by 25% and deacetylldithiasem by 18%; 1 for N-detylldithiazema

    Increase AUC by 20%

    Venlafaxine

    1

    1

    Flunarizine

    Increase AUC by 16% (50 mg every 12 hours) **

    1

    * - Expressed in% of the values ​​of Cmah in the blood plasma and A UC with monotherapy.

    1 - No change in Cmah in the blood plasma and AUC (<15% of the original data).

    ** - With repeated administration of a single flunarizine, an increase A UC by 14%, which may be due to the accumulation of the drug in the process of reaching the equilibrium state.

    NO - not investigated.

    Special instructions:

    Antiepileptic drugs should be withdrawn gradually to minimize the possibility of increasing the frequency of seizures. If a quick discontinuation of therapy is necessary for the patient, appropriate control should be established (see "Method of administration and dose"). As with other anticonvulsants, the frequency of seizures may increase at the onset of topiramate use, or a new type of seizure may occur.These phenomena can be caused by an overdose, a decrease in the concentration of concurrently used drugs, the progression of the disease, or a paradoxical reaction.

    Patients with moderate or severe renal dysfunction to achieve stable plasma concentrations may need 10 to 15 days, in contrast to 4-8 days in patients with normal renal function.

    As with any disease, the dose selection scheme should focus on the clinical effect (ie, the degree of control of seizures, the absence of side effects) and take into account the fact that patients with renal dysfunction to establish a stable concentration in the plasma for each dose may need more long time.

    Oligohydrosis

    In the treatment with topiramate, the occurrence of oligohydrosis (reduced sweating) is possible. Reducing sweating and hyperthermia (increased body temperature) can be particularly vulnerable to young children who are in a high ambient temperature. In the treatment with topiramate, sufficient hydration is required, which can reduce the risk of developing nephrolithiasis.below Sufficient hydration before and during physical exertion or exposure to high temperatures can reduce the risk of unwanted reactions due to thermal effects (see section "Side effect").

    Mood / depression

    When treating topiramate, there is an increased incidence of mood disorders and depression.

    Suicidal thoughts and attempts

    When using antiepileptic drugs, including topiramate, the risk of suicidal thoughts and suicidal behavior increases in patients taking these drugs for any of the indications.

    Meta-analysis of randomized placebo-controlled trials anticonvulsants showed an increased risk of suicidal ideation and suicidal behavior. The mechanism of this risk is unknown, the available data do not exclude the possibility of increasing the risk when using the drug.

    In double-blind clinical trials, the incidence of suicidal-related events (suicidal thoughts, suicide attempts, suicide) was 0.5% in patients who received topiramate (in 46 of 8652 patients), which is approximately 3 times higher compared to patients receiving placebo (0.2%, 8 patients out of 4045).

    Therefore, it is necessary to monitor the status of patients in order to identify signs of suicidal tendencies and prescribe appropriate treatment.

    It is necessary to recommend patients (and if necessary, carers of patients) immediately seek medical help in case of signs of suicidal tendencies or suicidal behavior.

    Nephrolithiasis

    In some patients, in particular those with a predisposition to urolithiasis, the risk of kidney stones and related symptoms such as renal colic, kidney or side pain may increase. Risk factors for the development of urolithiasis are: nephrolithiasis in the anamnesis (including in the family), hypercalciuria. None of these factors is an accurate predictor of nephrolithiasis when taking topiramate. In addition, the concomitant therapy with drugs that contribute to the development of nephrolithiasis is a risk factor.

    Impaired renal function

    In patients with renal insufficiency (CC ≤ 70 ml / min) topiramate should be administered with caution, as its plasma and renal clearance decreases. Recommendations for dosing in patients with renal insufficiency are presented in the section "Method of administration and dose" (subsection "Renal failure").

    Impaired liver function

    In patients with impaired hepatic function topiramate should be used with caution because of the possible reduction in the clearance of this drug.

    Myopia and secondary closed angle glaucoma

    With the use of topiramate, a syndrome including acute myopia with concomitant secondary closed angle glaucoma is described. Symptoms include acute visual acuity and / or eye pain. Ophthalmic examination can detect myopia, flattening of the anterior chamber of the eye, hyperemia (reddening) of the eyeball, increased intraocular pressure. There may be mydriasis. This syndrome can be accompanied by the secretion of fluid, leading to a shift in the lens and iris forward with the development of secondary closed-angle glaucoma. Symptoms usually appear during the first month of application of topiramate.Unlike primary open angle glaucoma, which is rare in patients under 40 years of age, secondary occlusive glaucoma is observed with topiramate in both adults and children. If a syndrome occurs that involves myopia associated with occlusive glaucoma, stop taking the drug as soon as the attending physician deems it possible, and take appropriate measures to lower the intraocular pressure. Usually these measures lead to normalization of intraocular pressure. Increased intraocular pressure of any etiology in the absence of adequate treatment can lead to serious complications, including loss of vision. When prescribing topiramate, patients with eye ailments in the anamnesis should evaluate the relationship of benefit to the possible risk of use.

    Defects of the field of view

    Defects of the visual field were observed in patients taking topiramate, regardless of their increased intraocular pressure. In clinical trials, most of these cases were reversible, disappeared after the abolition of therapy. If visually impaired, consider discontinuing therapy.

    Metabolic acidosis

    With the use of topiramate, hyperchloremic, not associated with an anion deficiency, metabolic acidosis (eg, a decrease in the level of hydrocarbonates in the plasma below the normal level in the absence of respiratory alkalosis) may occur. Such a decrease in serum bicarbonate concentration is a consequence of the inhibitory effect of topiramate on renal carboanhydrase. The degree of reduction in concentration is usually mild or moderate (mean value is 4 mmol / L when used in adults at a dose above 100 mg per day and about 6 mg / kg per day - when used in children). In rare cases, the patients had a decrease in the concentration of hydrocarbonates below 10 mmol / l. Some diseases or treatments that predispose to the development of acidosis (eg, kidney disease, severe Respiratory diseases, status epilepticus, diarrhea, surgical interventions, fat-rich food, intake of certain medications) may serve as additional factors that enhance the hydrocarbonate-lowering effect of topiramate.

    Chronic metabolic acidosis increases the risk of formation of urinary calculi and canlead to osteopenia.

    In children, chronic metabolic acidosis can lead to slower growth. The effect of topiramate on complications associated with the bone system in children and adults has not been systematically studied.

    Depending on the underlying disease in the treatment with topiramate, it is recommended that a proper assessment of the condition is carried out, including the determination of serum bicarbonate concentration. In the presence of signs or symptoms (eg, Kussmaul breathing, dyspnea, anorexia, nausea, vomiting, excessive fatigue, tachycardia, or arrhythmia), indicating metabolic acidosis, it is recommended to measure the content of bicarbonates in the blood serum. When developing and maintaining metabolic acidosis, you should consider reducing the dose or canceling topiramate (gradually).

    Topiramate should be used with caution in patients with metabolic acidosis or risk factors for its development.

    Cognitive impairment

    Cognitive impairment in epilepsy is multifactorial and may be due to a causative disease, epilepsy or antiepileptic therapy.In the literature, cognitive impairment was described in adults receiving topiramate treatment, requiring a reduction in dose or withholding therapy. However, a study on the effect on cognitive outcomes in children taking topiramate, are insufficient, and their influence on these parameters requires further study.

    Enhanced nutrition

    In the treatment of topiramate, some patients may have decreased body weight. In patients receiving topiramate, it is recommended to control body weight. If the patient loses body weight when treated with the drug, then it is necessary to consider the feasibility of enhanced nutrition.

    Effect on the ability to drive transp. cf. and fur:

    Topiramate acts on the central nervous system and can cause drowsiness, dizziness and other symptoms. It can also cause visual impairment. These adverse events may pose a risk to patients administering

    car and moving mechanisms, especially in the period until the patient's reaction to the drug is established.

    Form release / dosage:

    Film coated tablets, 25 mg, 50 mg and 100 mg.

    Packaging:

    For 14 tablets in a PVC / aluminum foil blister printed or 60 tablets in a polymer container with a screw cap and first opening control.

    For 2 blisters or 1 container, put in a pack of cardboard along with instructions for use.

    Storage conditions:

    In the dark place at a temperature of no higher than 25 ° C. Keep out of the reach of children.

    Shelf life:3 years. Do not use the drug after the expiration date.
    Terms of leave from pharmacies:On prescription
    Registration number:LP-004233
    Date of registration:06.04.2017
    Expiration Date:06.04.2022
    The owner of the registration certificate:VIAL, LLC VIAL, LLC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp17.05.2017
    Illustrated instructions
      Instructions
      Up